| Literature DB >> 24157873 |
D D H Tran1, S Saran, O Dittrich-Breiholz, A J K Williamson, S Klebba-Färber, A Koch, M Kracht, A D Whetton, T Tamura.
Abstract
Hematopoiesis and commitment to a restricted lineage are guided by a timely expressed set of cytokine receptors and their downstream transcription factors. A member of the mRNA export complex, THOC5 (suppressors of the transcriptional defects of hpr1 delta by overexpression complex 5) is a substrate for several tyrosine kinases such as macrophage colony-stimulating factor (M-CSF) receptor and various leukemogenic tyrosine kinases, such as Bcr-Abl, or NPM-ALK. THOC5 tyrosine phosphorylation is elevated in stem cells from patients with chronic myeloid leukemia, suggesting that THOC5 may be involved in leukemia development. THOC5 is also an essential element in the maintenance of hematopoiesis in adult mice. In this report, we show that THOC5 is located in the nuclear speckles, and that it is translocated from the nucleus to cytoplasm during M-CSF-induced bone marrow-derived macrophage differentiation. Furthermore, we have identified THOC5 target genes by trancriptome analysis, using tamoxifen-inducible THOC5 knockout macrophages. Although only 99 genes were downregulated in THOC5-depleted macrophages, half of the genes are involved in differentiation and/or migration. These include well-known regulators of myeloid differentiation inhibitor of DNA binding (Id)1, Id3, Smad family member 6 (Smad6) and Homeobox (Hox)A1. In addition, a subset of M-CSF-inducible genes, such as Ets family mRNAs are THOC5 target mRNAs. Upon depletion of THOC5, unspliced v-ets erythroblastosis virus E26 oncogene homolog (Ets1) mRNA was accumulated in the nucleus. Furthermore, THOC5 was recruited to chromatin where Ets1 was transcribed and bound to unspliced and spliced Ets1 transcripts, indicating that THOC5 has a role in processing/export of M-CSF-inducible genes. In conclusion, regulation of immediate-early gene response by THOC5, a member of mRNA export complex contributes to the M-CSF-induced macrophage differentiation.Entities:
Mesh:
Substances:
Year: 2013 PMID: 24157873 PMCID: PMC3920956 DOI: 10.1038/cddis.2013.409
Source DB: PubMed Journal: Cell Death Dis Impact factor: 8.469
Figure 1THOC5 is required for growth of bone marrow-derived macrophages in vitro. (a) Bone marrow cells were isolated from CreERT2 THOC5 (flox/flox) and ROSA26-CreERT2 (control) mice. Cells were incubated for an additional 3 days in L929 cell-conditioned medium. Cells were then treated with (+) or without (−) tamoxifen (10 μM) (tamoxifen treatment). Total cell lysates from a sister culture of bone marrow-adherent cells on day 3, 5 and 7 (arrows) after tamoxifen treatment were analyzed by THOC5, GAPDH, cleaved (Cl.) caspase 3 and caspase 3-specific immunoblot. As control for Cl. caspase 3 blot, macrophages were treated with etoposide for 8 h. (b) Cell numbers of sister macrophage cultures isolated from CreERT2 THOC5 (flox/flox) and ROSA26-CreERT2 (CreERT2 control) mice were counted on days 3 and 5 (arrows) after tamoxifen treatment (+) in the presence of M-CSF. As control, cells were incubated for same period without tamoxifen treatment (−). Average values from three independent experiments±S.D. are shown. Probability (P)-value: Student t-test. (c) Bone marrow cells from CreERT2 and CreERT2 THOC5 mice treated with tamoxifen (3 days) were stained with CD206 Alexa Fluor (AF) 488, CD45 Brilliant Violet (BV) 421, CD11c AF 647 and CD163 PE. To control for autoflourescence, cells were analyzed with no antibody labelling (unstained). Cell surface fluorescence intensity was assessed using flow cytometry
Figure 2Subcellular localization of THOC5 changes during macrophage differentiation. Bone marrow-adherent cells were prepared as described in Figure 1a, and further incubated in the presence of M-CSF. Four, 8, and 10 days after isolation, macrophages were fixed and stained with THOC5- or Aly-specific antibodies and FITC-conjugated secondary antibody, followed by DAPI (4,6-diamidino 2-phenylindole) staining
Figure 3Identification of THOC5-dependent genes in bone marrow-derived macrophages by transcriptome analysis. Bone marrow macrophages-derived from ROSA26-CreERT2 control and CreERT2 THOC5 (flox/flox) mice were treated with or without tamoxifen (Tam) in the presence of M-CSF for 3 days (3d samples). (a) Ratios from normalized fluorescence intensities were calculated from 3d samples /0d samples, and were finally converted into fold change values. Positive fold change values (color-coded in red) indicate an upregulation, whereas negative values (green color) indicate a downregulation during the 3 days of M-CSF-induced differentiation in two independent experiments (first experiment columns 1–4; second experiment columns 5–8). Directly adjacent lanes (columns 1+2, 3+4, 5+6 and 7+8) represent a comparison of non-treated, with tamoxifen-treated 3d samples. All samples were co-hybridized against the same common reference sample (0 day reference sample from the same mouse). In order to depict differences in mRNA expression between control and CreERT2 THOC5 (flox/flox) mice, ratios of ratios were calculated (as indicated in the header), converted into fold change values and depicted in a blue–grey color code. Blue color indicates an elevated relative expression with tamoxifen treatment, whereas grey indicates a decrease in expression with tamoxifen (first experiment, columns 9–10; second experiment columns 11–12). Finally, columns 13 and 14 represent the specificity of the THOC5 knockdown effects without tamoxifen side effects in experiments 1 and 2, respectively. (b) Transcriptional regulator genes that were downregulated by THOC5 depletion in macrophages. These transcripts were depicted along with color-coded fold-change values, accession numbers, Agilent probe IDs and official gene symbols. Classification was based on information from IPA
THOC5-dependent genes are involved in cellular development and cellular movement
| 1. Cellular Development | 33 | ||
| Differentiation | 25 | 1.77E-04 | |
| Proliferation | 18 | 7.65E-04–1.60E-02 | |
| Development of blood cells | 10 | 4.96E-03 | |
| 2. Cellular Movement | 27 | ||
| Migration | 24 | 6.81E-05 | |
| Extravasation | 5 | 8.77E-06 | |
| Adhesion | 4 | 9.88E-04 | |
| Homing | 5 | 5.09E-03 |
ACP5, acid phosphatase 5, tartrate resistant; AIF1, allograft inflammatory factor 1; ASB2, ankyrin repeat and SOCS box containing 2; ASCL2, achaete-scute complex homolog 2 (Drosophila); BMP1, bone morphogenetic protein 1; CCR5, chemokine (C-C motif) receptor 5; Cd55, CD55 antigen; CDH5, cadherin 5, type 2 (vascular endothelium); CDK5R1, cyclin-dependent kinase 5, regulatory subunit 1 (p35); CITED1, Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 1; ETV5, ets variant 5; F11R, F11 receptor; F13A1, coagulation factor XIII, A1 polypeptide; FCGR3A, Fc fragment of IgG, low affinity IIIa, receptor (CD16a); FGL2, fibrinogen-like 2; FUT7, fucosyltransferase 7 (alpha (1,3) fucosyltransferase); GPR56, G protein-coupled receptor 56; HOXA1, homeobox A1; HSD11B1, hydroxysteroid (11-beta) dehydrogenase 1; ID1, inhibitor of DNA binding 1, dominant negative helix-loop-helix protein; ID3, inhibitor of DNA binding 3, dominant negative helix-loop-helix protein; IL1B, interleukin 1, beta; ITGA9, integrin, alpha 9; ITGAL, integrin, alpha L (antigen CD11A (p180), lymphocyte function-associated antigen 1; alpha polypeptide); KALRN, kalirin, RhoGEF kinase; KLF2, Kruppel-like factor 2 (lung); LIFR, leukemia inhibitory factor receptor alpha; LMO1, LIM domain only 1 (rhombotin 1); LTB, lymphotoxin beta (TNF superfamily, member 3); MKL2, MKL/myocardin-like 2; NCOR1, nuclear receptor corepressor 1; NDRG1, N-myc downstream regulated 1; PECAM1, platelet/endothelial cell adhesion molecule 1; RASGRP1, RAS guanyl releasing protein 1 (calcium and DAG-regulated); Siglec5, sialic acid binding Ig-like lectin 5; SMAD6, SMAD family member 6; TCF7L2, transcription factor 7-like 2 (T-cell specific, HMG-box); TOP1, topoisomerase (DNA) I; TSPAN32, tetraspanin 32. Sixty-eight functionally known genes that were consistently downregulated by the depletion of THOC5 were analyzed by IPA Ingenuity analysis (Ingenuity System, Inc.). Transcription regulators are in bold
Figure 4Nuclear export of THOC5 target genes in bone marrow macrophages. (a) Bone marrow macrophages were isolated from CreERT2 THOC5 (flox/flox) or ROSA26-CreERT2 (control) mice as described (Figure 1a). Adherent cells were incubated with (+) and without (−) tamoxifen (10 μM) for 3 days, and nuclear (Nuc) and cytoplasmic (Cyt) RNAs were then isolated and applied for Etv5-, HoxA1-, HoxA9-, Id1-, Id3-, Smad6-, Ascl2-, THOC5- or actin-specific reverse transcriptase (RT)-PCR using primers as described in Supplementary Table S1 (RT-PCR, spliced). cDNA from all samples were standardized by adjusting equal levels of actin mRNA in both fractions (Supplementary Figure S2). Protein extracts were supplied for GAPDH- and Histone H3-specific immunoblot (Blot). We performed three independent experiments, and we show one example of representative data. (b) Signal intensity from Etv5-, HoxA1-, Id1- and actin-specific RT-PCR products was quantified using TINA 2.0 software. The percentage of signal intensity from the nuclear (Nuc) or the cytoplasmic (Cyt) fraction of total intensity (Nuc+Cyt) is shown. Average values±S.D. from three independent experiments are shown. (c) Control macrophages (5 days after isolation) were incubated in the absence of serum and M-CSF for 16 h and then stimulated with human M-CSF (100 ng/ml) for 1, 2, 4, 8 and 14 h. RNAs were isolated and supplied for Ets1-, Ets2-, Etv5-, Id1-, Id3- and GAPDH-specific RT-PCR. (a and c): the number of amplification cycles is shown in ‘cycles (n)'
Figure 5THOC5 is required for the processing of Ets1. (a) Human c-Fms cDNA was expressed in MEF (M-CSFR THOC5 (flox/flox) MEF) cells. After serum starvation for 24 h, cells were stimulated with human M-CSF (100 ng/ml) for 0.5, 2 and 4 h and cell extracts were then subjected to Fms-, phosphoErk (p-Erk1/2)-, Erk-, phosphoAkt (p-Akt)-, Akt-, and GAPDH-specific immunoblot. (b) M-CSFR (flox/flox) MEF cells were treated as described in (a) and were stimulated with M-CSF for 1, 2 and 4 h. Total RNAs were isolated and subjected to Ets1-, Ets2-, Etv5-, Egr1-, Id1-, Id3-, HoxA1- and GAPDH-specific reverse transcriptase (RT)-PCR. (c) Sister cultures of M-CSFR THOC5 (flox/flox) MEF were infected with Ad-GFP or Ad-GFP-Cre virus for 3 days. After serum starvation for 24 h, cells were stimulated with M-CSF for 1 and 2 h. Protein extract from cells before stimulation (0 h) were supplied for THOC5- and GAPDH-specific immunoblot (Blot). Total RNAs were isolated from each preparation and supplied for Ets1-, Ets2-, Egr1-, GAPDH- and THOC5-specific RT-PCR (RT-PCR). (d) Aliquots of cDNA samples from (c) were applied for quantitative RT-PCR analysis of Ets1 mRNA (TaqMan RT-PCR). Relative expression levels compared with GAPDH were normalized. Average values from four independent PCR reactions+S.D. are shown. (e) Cells were prepared as described in (c), but RNA and protein were isolated from the nuclear and the cytoplasmic fractions obtained from 5000 cells and then supplied for Ets1-, Ets2-, Egr1-, and GAPDH-specific RT-PCR. Protein extracts were supplied for GAPDH- and Histone H3-specific immunoblot. (f) RNA was isolated from the nuclear fraction as described in (a) and subjected to Ets1- and GAPDH-specific RT-PCR using an exon–intron primer pair as indicated. RNA samples were reverse transcribed using oligo dT or random hexamer (random) primer as indicated (Supplementary Table S1). As negative controls, RNA samples were supplied for PCR without reverse transcription (−). We performed independent experiments, and we show one example of representative data (a–f)
Figure 6THOC5 moves to the chromatin where the Ets1 gene was active and binds its target mRNAs. (a) pCTAP (TAP) and pCTAP carrying THOC5 cDNA (TAP-THOC5) were transfected into M-CSFR-THOC5 (flox/flox) MEF cells and were incubated for 24 h in the presence of 10% FCS. After serum starvation for 24 h, cells were stimulated with (+) or without (−) M-CSF for 2 h. After cross-linking by adding formaldehyde, protein and DNA were extracted and the chromatin was sheared by sonication. Cell extracts (Input 1/20) and binding fractions with Streptavidin Sepharose or immunoprecipitates using pS5 CTD (pS5 Ab) or control IgG were analyzed by Ets1 (promoter region and exon 8), and Egr1 (promoter region and exon 2) specific PCR (Supplementary Table S1;ChIP). The promoter region of each gene was described by Zhao et al.[43] Numbers represent nucleotide numbers from the initiation site for each gene.[44] (b) pCTAP and pCTAP carrying THOC5 cDNA (TAP-THOC5) were transfected into M-CSFR THOC5 (flox/flox) MEF cells and were then incubated further for 24 h in the presence of 10% FCS. After serum starvation for 24 h, cells were stimulated with (+) or without (−) M-CSF for 4 h. Cell extracts (Input) and binding fractions with Streptavidin Sepharose (Bound) were analyzed by THOC5-specific immunoblot (Blot). The same samples were analyzed by Ets1-, Ets2-, Etv5-, Egr1- and GusB-specific reverse transcriptase (RT)-PCR (RT-PCR). endo-THOC5, endogenous THOC5. (c) The same samples without M-CSF stimulation were analyzed by Id1-, Id3-, HoxA1- and HoxA9-specific RT-PCR (35 cycles) (RT-PCR). We performed three independent experiments and we show one example of representative data (a–c)
Figure 7Scheme of summary. Upon stimulation with M-CSF, numbers of immediate-early response genes (IEG) are induced. We propose that co-transcriptionally spliced or intron-less immediate-early genes, such as Jun, Fos, or Egr1 are further processed without THOC5, while THOC5 is required for the processing of a subset of immediate-early genes, whereby THOC5 is recruited to chromatin where genes were activated, and participate in further processing of these mRNAs. THOC5-dependent genes have a key role in maintenance of the differentiation/proliferation at early stage of differentiation process. When macrophages are terminally differentiated, THOC5 is located in the cytoplasm and does not have a role in mRNA processing